Market Research Report New Study on US Drug Eluting Sinus Stent (DESS) M | Page 3

Medical management includes antibiotics and oral and nasal steroids. The sinus surgeries are mainly of two types: Functional Endoscopic Sinus Surgery( FESS) and Balloon Sinus Dilation( BSD).
Intersect, is the only company that has developed drug releasing bio-absorbable implants( drug eluting sinus stents- DESS) that enable targeted and sustained release of therapeutic agents, increasing the effectiveness of the sinus surgery.
The US DESS market is expected to increase at a significant growth rate during the forecasted period( 2016-2021). The US DESS market is supported by various growth drivers, such as limitations of FESS treatment, benefits of DESS, increasing per capita healthcare expenditure, cost effectiveness of DESS, etc. Yet, the market faces certain challenges, such as, reimbursement issues, dependability on individual physician’ s experience, limited trials after BSD, etc.
Request a sample of US Drug Eluting Sinus Stent( DESS) market @ http:// www. orbisresearch. com / contacts / request-sample / 185412.
Some points from TOC: 1. Executive Summary
2. Introduction 2.1 Sinus Overview 2.1.1 Types of Sinus 2.2 Sinusitis Overview 2.2.1 Types of Sinusitis 2.2.2 Treatment Options 2.3 Drug Eluting Sinus Stents( DESS) Overview
For any enquires before buying, connect with us @ enquiry @ orbisresearch. com About Us:
Orbis Research( orbisresearch. com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information: Hector Costello Senior Manager – Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas – 75204, U. S. A.
www. orbisresearch. com; + 1( 214) 884-6817; + 9120-64101019